Flu Vaccines: Current and Novel Approach

Flu Vaccine is an annual vaccination using a vaccine that is specific for a given year to protect against the highly variable influenza virus. Risk management and effectiveness of vaccines are important for public health. In the United States, NIAID laboratories are developing novel vaccine candidates for seasonal influenza viruses and for avian strains with pandemic potential. In late 2006, the NIAID Vaccine Research Center initiated the first human trial of an investigational DNA vaccine against the H5N1 avian influenza virus, a strain that has infected and continues to threaten humans. In addition, researchers in the NIAID Laboratory of Infectious Diseases are working with MedImmune to generate candidate live-attenuated vaccines for a broad range of influenza subtypes with pandemic potential. To date, five of these vaccine candidates have advanced to Phase I clinical trials. Many Ebola vaccine candidates had been developed in the decade prior to 2014, but none has yet been approved for clinical use in humans.

Flu Vaccine can be defined as a biological preparation that provides active acquired immunity to a flu disease. Flu vaccination by injection, commonly known as the "flu jab" is available every year on the for adults (and some children) at risk of flu and its complications. For improving vaccine immunogenicity adjuvants are used. Vaccine Adjuvants – It can be defined as a component which potentiates the immune system and accelerates the immune responses to an antigen.These components act to induce, prolong, and enhance antigen-specific immune responses when used in combination with specific vaccine antigens.  Aluminum salts are the only licensed adjuvant in the United States, but the combination of these salts with inactivated influenza A/H5N1 antigens has had little effect on seroresponses. Several oil-in-water adjuvants, including MF59 and AS03, have significantly enhanced immune responses in healthy adult vaccine recipients to inactivated influenza A/H5N1.

 

  • Genetic and evolution of virus and host
  • Risk management and effectiveness of vaccines
  • Targeting strategies for influenza vaccines
  • Adjuvants and their improvement issues
  • Clinical trails of influenza based vaccines
  • Epidemiology and prevention of vaccine
  • Ebola Vaccine

Related Conference of Flu Vaccines: Current and Novel Approach

October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA
November 06-07, 2017

3rd International Conference on Flu and Emerging Infectious Diseases

Las Vegas, Nevada, USA
December 07-08, 2017

EuroSciCon Conference on STD-AIDS

Rome, Italy
March 1-2, 2018

5th International congress on Infectious Diseases

Berlin, Germany
June 11-12, 2018

4th World Congress on Rare Diseases and Orphan Drugs

Dublin, Ireland
July 23-25, 2018

11th World Congress on Infectious Diseases and Therapy

Melbourne, Australia
August 13-14,2018

Global Experts Meeting on Infectious Diseases

Tokyo,Japan
August 27-28, 2018

9th International Conference on Emerging Infectious Diseases

Zurich, Switzerland
September 17-18, 2018

4th Annual Congress on Infectious Diseases

San Diego, USA
September 27-29, 2018

10thEuro-Global Conference on Infectious Diseases

Rome, Italy

Flu Vaccines: Current and Novel Approach Conference Speakers

Recommended Sessions

Related Journals

Are you interested in